Get startedLog in
    Picture of Eli Lilly and logo

    LLY — Eli Lilly and News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareBalancedLarge CapHigh Flyer
    All News

    Brief: Eli Lilly - Foundayo 17.2 Mg Associated With 57% Reduction In Diabetes Risk, 18% In Cardiovascular Risk Versus Placebo

    Picture of Eli Lilly and logoEli Lilly and
    01/10/2026 12:01
    BRIEF-Eli Lilly - Foundayo 17.2 Mg Associated With 57% Reduction In Diabetes Risk, 18% In Cardiovascular Risk Versus Placebo
    Oct 1 (Reuters) - Eli Lilly and Company LLY.N:
    • ELI LILLY - FOUNDAYO 17.2 MG ASSOCIATED WITH 57% REDUCTION IN DIABETES RISK, 18% IN CARDIOVASCULAR RISK VERSUS PLACEBO
    • ELI LILLY - FOUNDAYO ASSOCIATED WITH REDUCED PREDICTED LONG-TERM RISK OF TYPE 2 DIABETES AND CARDIOVASCULAR DISEASE
    Source text: ID:nPn3mXKdqa
    Further company coverage: LLY.N

     ((Reuters.Briefs@thomsonreuters.com;;))

    Recent news on Eli Lilly and

    See all news